MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Study Goal
The researchers aimed to comprehensively evaluate the efficacy and safety of MDMA-assisted psychotherapy (MDMA-AT) for treating chronic, treatment-resistant PTSD.
Results Summary
MDMA-AT significantly reduced PTSD symptom severity (CAPS-5 scores) and improved response and remission rates compared to controls, with no significant difference in adverse events or suicidal ideation between groups.
Population
297 participants with chronic, treatment-resistant PTSD.
Effective Dosage
Inactive doses of MDMA (25-40 mg) in the control group; active doses not specified in the abstract.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
MDMA-assisted psychotherapy (MDMA-AT) | decrease | Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) severity scores | participants with PTSD | SMD -1.10, 95% CI: -1.62 to -0.59 | led to a significant reduction | #1 |
MDMA-assisted psychotherapy (MDMA-AT) | increase | significant response | patients in the MDMA-AT group | RR 1.59, 95% CI: 1.22, 2.08 | More patients exhibited significant response | #2 |
MDMA-assisted psychotherapy (MDMA-AT) | increase | remission | patients in the MDMA-AT group | RR 2.32, 95% CI: 1.47 to 3.66 | More patients exhibited remission | #3 |
MDMA-assisted psychotherapy (MDMA-AT) | no change | ≥1 treatment-emergent adverse events (TEAE) | participants with PTSD | no significant difference | no significant difference regarding the incidence | #4 |
MDMA-assisted psychotherapy (MDMA-AT) | no change | ≥1 severe TEAE | participants with PTSD | no significant difference | no significant difference regarding the incidence | #5 |
MDMA-assisted psychotherapy (MDMA-AT) | no change | suicidal ideation | participants with PTSD | no significant difference | no significant difference regarding the incidence | #6 |
BACKGROUND: Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating symptoms. Despite available treatments, many individuals experience inadequate response or significant side effects. Previous reviews suggest promising outcomes with MDMA-assisted psychotherapy (MDMA-AT), but limitations prompt the need for a comprehensive evaluation. METHODS: We searched various online databases and registries such as MEDLINE (via PubMed), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov to retrieve RCTs that fit our inclusion criteria. We performed meta-analyses using Review Manager by applying a random-effects model. Dichotomous and continuous outcomes were pooled as risk ratios (RR) and standard mean difference (SMD), respectively. RESULTS: Nine studies with a total of 297 participants with PTSD were included in our meta-analysis. The control group consisted of inactive doses of MDMA (25-40 mg) or placebo. Our meta-analysis showed that MDMA-AT led to a significant reduction in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) severity scores as compared to the control group (SMD -1.10, 95% CI: -1.62 to -0.59). More patients in the MDMA-AT group exhibited significant response (RR 1.59, 95% CI: 1.22, 2.08) and remission (RR 2.32, 95% CI: 1.47 to 3.66) as compared to patients in the control group. There was no significant difference regarding the incidence of ≥1 treatment-emergent adverse events (TEAE), ≥1 severe TEAE, and suicidal ideation between the two groups. CONCLUSION: MDMA-AT demonstrates significant efficacy in improving PTSD symptoms, enhancing both response and remission rates in individuals with chronic, treatment-resistant PTSD, while maintaining a favorable safety profile.